New Zealand markets closed

NVS Apr 2023 77.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.2500-0.1000 (-28.57%)
At close: 02:15PM EDT
Full screen
Previous close0.3500
Expiry date2023-04-21
Day's range0.2500 - 0.3000
Contract rangeN/A
Open interest604
  • Zacks

    Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

    The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

  • Financial Times

    Novartis scraps drug trial in blow to UK life sciences ambitions

    A Swiss pharmaceutical group has scrapped plans to conduct a major drug trial in the UK, damaging government efforts to showcase the country as an attractive destination for investment in life sciences after Brexit. Three years ago Novartis’s decision to collaborate with the NHS on rolling out inclisiran, a twice-yearly injectable drug for lowering cholesterol, was announced to fanfare, after the UK’s slow take-up of innovative medicines compared with peers was criticised. Matt Hancock, health secretary at the time, described it as “a strong vote of confidence in our world-leading life sciences sector”.

  • GlobeNewswire

    Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulationSandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimil